GHR-2 (GHRP-2)
A synthetic growth hormone secretagogue that stimulates natural GH release, studied for body composition, recovery, and anti-aging.
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
What is GHR-2 (GHRP-2)?
GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide that acts as a potent growth hormone secretagogue. It stimulates the pituitary gland to release growth hormone through the ghrelin receptor (GHS-R1a). It is one of the most studied GHRPs and has been used as a diagnostic tool for growth hormone deficiency.
Why People Talk About It
Growth hormone optimization
ModerateImproved body composition
ModerateEnhanced recovery from training
EmergingImproved sleep quality
EmergingHow It Works
GHRP-2 tells your pituitary gland to release more growth hormone by mimicking a natural hunger hormone called ghrelin. This results in a pulse of growth hormone similar to what your body produces naturally during deep sleep.
Common Questions
Safety Information
Common Side Effects
Cautions
- • Not FDA-approved for anti-aging
- • Can affect blood sugar levels
- • Should be monitored by clinician
- • May affect cortisol and prolactin
What We Don't Know
Long-term effects of sustained GH elevation through GHRP-2 use are not fully characterized in anti-aging contexts.
Published Research
34 studiesObese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake
Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness
Preservation of growth hormone secretion in response to growth hormone-releasing peptide-2 during prednisone therapy
Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure
Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion
Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children
Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature
Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature
Comparison of pituitary-adrenal responsiveness between insulin tolerance test and growth hormone-releasing peptide-2 test: a pilot study
Diagnostic usefulness of the growth hormone-releasing peptide-2 test as a substitute for the insulin tolerance test in hypopituitarism
Chicken ghrelin and growth hormone-releasing peptide-2 inhibit food intake of neonatal chicks
Characteristics of growth hormone secretion responsiveness to growth hormone-releasing peptide-2 (GHRP-2 or KP102) in calves
Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2
Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN
Concordant and discordant adrenocorticotropin (ACTH) responses induced by growth hormone-releasing peptide-2 (GHRP-2), corticotropin-releasing hormone (CRH) and insulin-induced hypoglycemia in patients with hypothalamopituitary disorders: evidence for direct ACTH releasing activity of GHRP-2
Exaggerated response of adrenocorticotropic hormone to growth hormone-releasing peptide-2 test in Cushing's disease. Case report
Growth Hormone-Releasing Peptide 2 May Be Associated With Decreased M1 Macrophage Production and Increased Histologic and Biomechanical Tendon-Bone Healing Properties in a Rat Rotator Cuff Tear Model
Assessment of anterior pituitary reserve capacity based on growth hormone response to growth hormone-releasing peptide-2 test in the elderly
Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder
Evaluation of growth hormone-releasing peptide-2 for diagnosis of thyrotropin-producing pituitary adenomas
Growth Hormone Releasing Peptide-2 Attenuation of Protein Kinase C-Induced Inflammation in Human Ovarian Granulosa Cells
Synthesis of Mono-PEGylated Growth Hormone Releasing Peptide-2 and Investigation of its Biological Activity
One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient
Growth hormone response to growth hormone-releasing peptide-2 in growth hormone-deficient little mice
Identification of the growth-hormone-releasing peptide-2 (GHRP-2) in a nutritional supplement
Growth hormone releasing peptide-2, a ghrelin agonist, attenuates lipopolysaccharide-induced acute lung injury in rats
Influence of intravenous administration of growth hormone releasing peptide-2 (GHRP-2) on detection of growth hormone doping: growth hormone isoform profiles in Japanese male subjects
Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry
Growth hormone-releasing peptide-2 stimulates secretion and synthesis of adrenocorticotropic hormone in mouse pituitary
The effect of growth hormone releasing peptide-2 on upper gastrointestinal contractile activity and food intake in conscious dogs
Effect of growth hormone-releasing peptide-2 (GHRP-2) and GH-releasing hormone (GHRH) on the the cAMP levels and GH release from cultured acromegalic tumours
The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine
Effects of the administration of growth hormone-releasing peptide-2 (GHRP-2) orally by gavage and in feed on growth hormone release in swine
Effects of growth hormone-releasing peptide-2 (GHRP-2) on membrane Ca2+ permeability in cultured ovine somatotrophs
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
Related Peptides
CJC-1295
ModerateBeginnerA growth hormone-releasing hormone analog that stimulates the pituitary gland to produce more growth hormone.
Ipamorelin
ModerateBeginnerA selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.
Sermorelin
StrongBeginnerA growth hormone-releasing hormone analog that was previously FDA-approved for diagnosing GH deficiency in children.
MK-677
ModerateAn orally active growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release.
Quick Facts
- Class
- Growth Hormone Secretagogue
- Evidence
- Moderate
- Safety
- Moderate Data
- Updated
- Feb 2026
- Citations
- 34PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.
Interested in this peptide? A Noho clinician can help determine if it's right for you.
Talk to a Clinician